Latest News for NGENF
Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of life in chronic spinal cord injury VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage…
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for NGENF.
Senate Trading
No Senate trades found for NGENF.
U.S. House Trading
No House trades found for NGENF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.